New hope for tough esophageal cancer: QLC5508 faces chemotherapy in phase 3 showdown
NCT ID NCT07463573
First seen Mar 20, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study tests a new drug called QLC5508 against standard chemotherapy for people with advanced esophageal cancer that has worsened after prior treatments. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main goal is to see if QLC5508 helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.